+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Tetanus - Pipeline Review, H2 2019

  • ID: 4866513
  • Drug Pipelines
  • November 2019
  • Region: Global
  • 78 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Biken Co Ltd
  • BioNet- Asia Co Ltd
  • CanSino Biologics Inc
  • GlaxoSmithKline Plc
  • LG Chem Ltd
  • Panacea Biotec Ltd
  • MORE
Tetanus - Pipeline Review, H2 2019

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Tetanus - Pipeline Review, H2 2019, provides an overview of the Tetanus (Infectious Disease) pipeline landscape.

Tetanus is a serious illness caused by Clostridium bacteria. Signs and symptoms of tetanus include spasms and stiffness in jaw muscles, difficulty swallowing, stiffness of abdominal muscles, fever, sweating, elevated blood pressure and rapid heart rate. The predisposing factors include burns, surgical wounds, ear infections, swelling around the injury and infected foot ulcers. Treatment includes antibiotics, sedatives and beta blockers.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Tetanus - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Tetanus (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tetanus (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Tetanus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 5, 6, 1, 10, 1 and 1 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 1 and 1 molecules, respectively.

Tetanus (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Tetanus (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Tetanus (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Tetanus (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Tetanus (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Tetanus (Infectious Disease)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Tetanus (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Tetanus (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Biken Co Ltd
  • BioNet- Asia Co Ltd
  • CanSino Biologics Inc
  • GlaxoSmithKline Plc
  • LG Chem Ltd
  • Panacea Biotec Ltd
  • MORE
Introduction
Report Coverage
Tetanus - Overview
Tetanus - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Tetanus - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Tetanus - Companies Involved in Therapeutics Development
Beijing Minhai Biotechnology Co Ltd
Beijing Tiantan Biological Products Co Ltd
Biken Co Ltd
Biological E Ltd
BioNet- Asia Co Ltd
Boryung Pharmaceutical Co Ltd
Cadila Healthcare Ltd
CanSino Biologics Inc
Changchun Bcht Biotechnology Co Ltd
Chongqing Zhifei Biological Products Co Ltd
GC Pharma
GlaxoSmithKline Plc
KM Biologics Co Ltd
LG Chem Ltd
Novo Medi Sciences Pvt Ltd
NTxBio LLC
Olymvax Biopharmaceuticals Inc
Panacea Biotec Ltd
Sanofi Pasteur SA
Seasons Healthcare Ltd
Serum Institute of India Ltd
Shantha Biotechnics Pvt Ltd
Sichuan ZehaTimes Pharmaceutical Co Ltd
Yisheng Biopharma Co Ltd
Yuxi Jiuzhou Biological Technology Co Ltd
Tetanus - Drug Profiles
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenza [serotype B] + meningococcal + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + polio + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenza [serotype B] + pertussis (acellular) + poliomyelitis + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenza [serotype B] + pertussis (acellular) + tetanus) (tetravalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + hepatitis B + meningococcal [serotype C] + pertussis (whole cell) + poliomyelitis + tetanus) (heptavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + poliomyelitis + tetanus) (hexavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + haemophilus influenzae [serotype B] + hepatitis B + pertussis (whole cell) + tetanus) (pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + Haemophilus influenzae [serotype B] + pertussis (whole cell) + polio + tetanus)(pentavalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) +
(diphtheria + pertussis (acellular) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (acellular) + tetanus) vaccine 2 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (whole cell) + tetanus) (trivalent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis (whole cell) + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis + tetanus) (acellular, adsorbed) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + pertussis + tetanus) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular) + poliomyelitis) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis (acellular)) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(diphtheria + tetanus + pertussis + poliomyelitis + haemophilus influenzae [serotype B]) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Adacel plus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antibody for Tetanus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-1004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BK-1310 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DTcP vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-3104A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GC-3111A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KD-370 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LBVD - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody for Tetanus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTXV-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tetanus vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Tetanus - Dormant Projects
Tetanus - Discontinued Products
Tetanus - Product Development Milestones
Featured News & Press Releases
Jan 14, 2019: FDA approves expanded use of Adacel (Tdap) vaccine for repeat vaccination
Mar 17, 2015: Sanofi: Shantha Will Provide Up To 37 Million Doses Of Shan5
Nov 24, 2014: CanSinotech submitted CTA of “Diphtheria and Tetanus Toxoids and Component Pertussis Vaccine Adsorbed” to CFDA
Nov 10, 2014: Shantha’s Pentavalent Pediatric Vaccine launched in India
May 05, 2014: Shantha’s Pentavalent Pediatric Vaccine prequalified by World Health Organization
Apr 01, 2014: Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age
May 11, 2011: Sanofi Pasteur Launches Pentaxim In China
Jul 25, 2005: Sanofi pasteur Begins Shipping ADACEL Vaccine in the U.S. for Combined Protection against Tetanus, Diphtheria, and Pertussis
Jun 13, 2005: U.S. FDA Licenses sanofi pasteur’s ADACEL Vaccine for Combined Protection Against Tetanus, Diphtheria and Pertussis
Jun 10, 2005: Society for Adolescent Medicine Statement on the FDA Licensure of Adacel Vaccine
Mar 18, 2005: FDA Advisory Panel Recommends Licensure of sanofi pasteur’s ADACEL Vaccine for Combined Protection against Tetanus, Diphtheria and Pertussis
Aug 11, 2004: Aventis Submits Application for FDA Licensure of ADACEL Vaccine for Prevention of Tetanus, Diphtheria and Pertussis in Adolescents and Adults.
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Table 1: Number of Products under Development for Tetanus, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Universities/Institutes, H2 2019
Table 5: Products under Development by Companies, H2 2019
Table 6: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 7: Products under Development by Universities/Institutes, H2 2019
Table 8: Number of Products by Stage and Target, H2 2019
Table 9: Number of Products by Stage and Mechanism of Action, H2 2019
Table 10: Number of Products by Stage and Route of Administration, H2 2019
Table 11: Number of Products by Stage and Molecule Type, H2 2019
Table 12: Tetanus - Pipeline by Beijing Minhai Biotechnology Co Ltd, H2 2019
Table 13: Tetanus - Pipeline by Beijing Tiantan Biological Products Co Ltd, H2 2019
Table 14: Tetanus - Pipeline by Biken Co Ltd, H2 2019
Table 15: Tetanus - Pipeline by Biological E Ltd, H2 2019
Table 16: Tetanus - Pipeline by BioNet- Asia Co Ltd, H2 2019
Table 17: Tetanus - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2019
Table 18: Tetanus - Pipeline by Cadila Healthcare Ltd, H2 2019
Table 19: Tetanus - Pipeline by CanSino Biologics Inc, H2 2019
Table 20: Tetanus - Pipeline by Changchun Bcht Biotechnology Co Ltd, H2 2019
Table 21: Tetanus - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H2 2019
Table 22: Tetanus - Pipeline by GC Pharma, H2 2019
Table 23: Tetanus - Pipeline by GlaxoSmithKline Plc, H2 2019
Table 24: Tetanus - Pipeline by KM Biologics Co Ltd, H2 2019
Table 25: Tetanus - Pipeline by LG Chem Ltd, H2 2019
Table 26: Tetanus - Pipeline by Novo Medi Sciences Pvt Ltd, H2 2019
Table 27: Tetanus - Pipeline by NTxBio LLC, H2 2019
Table 28: Tetanus - Pipeline by Olymvax Biopharmaceuticals Inc, H2 2019
Table 29: Tetanus - Pipeline by Panacea Biotec Ltd, H2 2019
Table 30: Tetanus - Pipeline by Sanofi Pasteur SA, H2 2019
Table 31: Tetanus - Pipeline by Seasons Healthcare Ltd, H2 2019
Table 32: Tetanus - Pipeline by Serum Institute of India Ltd, H2 2019
Table 33: Tetanus - Pipeline by Shantha Biotechnics Pvt Ltd, H2 2019
Table 34: Tetanus - Pipeline by Sichuan ZehaTimes Pharmaceutical Co Ltd, H2 2019
Table 35: Tetanus - Pipeline by Yisheng Biopharma Co Ltd, H2 2019
Table 36: Tetanus - Pipeline by Yuxi Jiuzhou Biological Technology Co Ltd, H2 2019
Table 37: Tetanus - Dormant Projects, H2 2019
Table 38: Tetanus - Dormant Projects, H2 2019 (Contd..1), H2 2019
Table 39: Tetanus - Discontinued Products, H2 2019

List of Figures
Figure 1: Number of Products under Development for Tetanus, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Targets, H2 2019
Figure 5: Number of Products by Stage and Targets, H2 2019
Figure 6: Number of Products by Routes of Administration, H2 2019
Figure 7: Number of Products by Stage and Routes of Administration, H2 2019
Figure 8: Number of Products by Molecule Types, H2 2019
Figure 9: Number of Products by Stage and Molecule Types, H2 2019
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Beijing Minhai Biotechnology Co Ltd
  • Beijing Tiantan Biological Products Co Ltd
  • Biken Co Ltd
  • Biological E Ltd
  • BioNet- Asia Co Ltd
  • Boryung Pharmaceutical Co Ltd
  • Cadila Healthcare Ltd
  • CanSino Biologics Inc
  • Changchun Bcht Biotechnology Co Ltd
  • Chongqing Zhifei Biological Products Co Ltd
  • GC Pharma
  • GlaxoSmithKline Plc
  • KM Biologics Co Ltd
  • LG Chem Ltd
  • Novo Medi Sciences Pvt Ltd
  • NTxBio LLC
  • Olymvax Biopharmaceuticals Inc
  • Panacea Biotec Ltd
  • Sanofi Pasteur SA
  • Seasons Healthcare Ltd
  • Serum Institute of India Ltd
  • Shantha Biotechnics Pvt Ltd
  • Sichuan ZehaTimes Pharmaceutical Co Ltd
  • Yisheng Biopharma Co Ltd
  • Yuxi Jiuzhou Biological Technology Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll